Skip to main content

4 Result(s)

within Caitriona Holohan Remove this filter

and

  1. Article

    Open Access

    The SCFSkp2 ubiquitin ligase complex modulates TRAIL-R2-induced apoptosis by regulating FLIP(L)

    TRAIL-R2 (DR5) is a clinically-relevant therapeutic target and a key target for immune effector cells. Herein, we identify a novel interaction between TRAIL-R2 and the Skp1-Cullin-1-F-box (SCF) Cullin-Ring E3 ...

    Jamie Z. Roberts, Caitriona Holohan, Tamas Sessler… in Cell Death & Differentiation (2020)

    Download PDF (4791 KB) View Article

  2. Article

    Open Access

    Pevonedistat (MLN4924): mechanism of cell death induction and therapeutic potential in colorectal cancer

    Pevonedistat (MLN4924), a selective inhibitor of the NEDD8-activating enzyme E1 regulatory subunit (NAE1), has demonstrated significant therapeutic potential in several malignancies. Although multiple mechanis...

    Jennifer Ferris, Margarita Espona-Fiedler, Claudia Hamilton… in Cell Death Discovery (2020)

    Download PDF (2496 KB) View Article

  3. Article

    Open Access

    Cytoplasmic FLIP(S) and nuclear FLIP(L) mediate resistance of castrate-resistant prostate cancer to apoptosis induced by IAP antagonists

    Expression of tumor necrosis factor-α (TNFα) in the serum of prostate cancer patients is associated with poorer outcome and progression to castrate-resistant (CRPC) disease. TNFα promotes the activity of NFκB,...

    Christopher McCann, Nyree Crawford, Joanna Majkut… in Cell Death & Disease (2018)

    Download PDF (1383 KB) View Article

  4. No Access

    Article

    Cancer drug resistance: an evolving paradigm

  5. Tumour resistance to chemotherapy and molecularly targeted therapies limits the effectiveness of current cancer therapies.

  6. ...

    7. Caitriona Holohan, Sandra Van Schaeybroeck, Daniel B. Longley… in Nature Reviews Cancer (2013)